The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The global chemotherapy-induced anemia market is expected to grow from $2.21 billion in 2022 to $2.40 billion in 2023 at a compound annual growth rate (CAGR) of 8.7%. The chemotherapy-induced anemia market is expected to reach $3.2 billion in 2027 at a CAGR of 7.6%.

North America held the largest chemotherapy-induced anemia market share, and Asia-Pacific was the fastest-growing region in 2022.

Chemotherapy-Induced Anemia Market Driver
The high prevalence of cancer and anemia is expected to propel the growth of the chemotherapy-induced anemia market going forward. Cancer is a disease where somebody’s cells grow out of control and spread to other body regions. In cancer patients receiving aggressive chemotherapy, whether with or without radiation therapy, cancer and chemotherapy-induced anemia (CIA) are frequent occurrences. The medication stimulates the production of red blood cells in the bone marrow and can be used to treat chemotherapy-induced anemia. For instance, in 2023, according to Cancer Research UK, a UK-based independent cancer research organization, the incidence of head and neck cancer in the UK is projected to rise by 3% between 2023 and 2025, while deaths due to head and neck cancers are expected to increase by 12% between 2023 and 2025. Therefore, the high prevalence of cancer and anemia drives the growth of the chemotherapy-induced anemia market.

View More On The Chemotherapy-Induced Anemia Market Report 2023 – https://www.thebusinessresearchcompany.com/report/chemotherapy-induced-anemia-global-market-report

Prominent Chemotherapy-Induced Anemia Market Trend
Product innovation is a key trend gaining popularity in the chemotherapy-induced anemia market. Major companies operating in the chemotherapy-induced anemia market are focused on developing innovative products to strengthen their position in the market. For instance, in November 2020, Astellas Pharma Inc, a Japan-based pharmaceutical company, and FibroGen, a US-based biotechnology company, received approval for EVRENZO (Roxadustat) in Japan for the treatment of anemia of chronic kidney disease in adult patients not on dialysis. Further, in May 2023, it released encouraging topline results from the company’s Phase III clinical trial in China using Roxadustat to treat anemia in patients receiving concurrent chemotherapy for non-myeloid cancers.

Chemotherapy-Induced Anemia Market Prominent Players
Major players in the chemotherapy-induced anemia market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Fresenius Kabi AG, Hospira Inc., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., 3SBio Group, FibroGen Inc., Karger AG, Avesthagen Ltd., Blausen Medical Communications Inc., and Aileron Therapeutics Inc.

Request A Sample Of The Global Chemotherapy-Induced Anemia Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=12513&type=smp

Key Chemotherapy-Induced Anemia Market Segments
The global chemotherapy-induced anemia market is segmented –
1) By Anemia: Mild Anemia, Moderate Anemia, Severe Anemia, Life-Threatening Anemia
2) By Treatment Type: RBC (Red Blood Cells) Transfusion, Erythropoiesis-Stimulating Agents (ESAs), Iron Supplementation
3) By End-User: Hospitals, Ambulatory Surgical Centers, Multispecialty Clinics, Cancer Research Centers,Cancer Rehabilitation Centers

The Chemotherapy-Induced Anemia Global Market Report 2023  provides a comprehensive overview on the chemotherapy-induced anemia market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the chemotherapy-induced anemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
Interventional Oncology Devices Global Market Report 2023
Immuno-Oncology Drugs Global Market Report 2023
Oncology Molecular Diagnostics Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company 
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model